Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences adopts change in control severance program for executives

Neutral Impact 3 of 5 leadership Written later

Integra LifeSciences adopted a change in control severance program on December 11, 2025, covering executives including CFO Lea Knight. The program takes effect January 1, 2026, and renews a program scheduled to expire December 31, 2025, and it pays severance only after a qualifying termination within two years of a change in control that occurs by December 31, 2026. The filing sets the benefit terms and does not describe any change in leadership.

Key points

  • Program adopted December 11, 2025, effective January 1, 2026, and renews a program due to expire December 31, 2025
  • Lump sum severance of 1.5 times salary plus target bonus, or 2 times for CFO Lea Knight, after a qualifying termination
  • Participants include Lea Knight (EVP and CFO), Robert T. Davis, Jr., Michael McBreen, and Harvinder Singh
  • Benefits include COBRA premium support for up to 18 months and outplacement services for up to 12 months

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECDec 12, 2025, 4:31 PM ET
Accession number0000917520-25-000100

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 12, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.